PGEN Soars 18% But Bearish Tech Signals Warn of Volatility

Market Snapshot

Shares of Precigen (PGEN.O) have surged 18.35% recently, but technical indicators suggest a weak market trend, with bearish signals dominating over bullish ones. Investors should proceed with caution as the stock remains volatile.

News Highlights

1. Automated Cell Processing Market Growth – A recent market report highlights that the automated cell processing systems industry is set to grow at a 16% CAGR through 2035. This could benefit Precigen and other biotech firms involved in cell therapy.

2. Global Supply Chain Concerns – Ongoing geopolitical tensions in West Asia could cost Indian drugmakers up to $750 million, potentially affecting global pharmaceutical supply chains. This could impact Precigen’s operations or partnerships in the region.

3. Nuvation Bio Acquires Safusidenib Rights – Nuvation Bio’s recent acquisition of rights to Safusidenib from Daiichi Sankyo underscores growing interest in drug development partnerships. This type of activity could inspire similar developments for Precigen in the near future.

Analyst Views & Fundamentals

Analyst Ratings

Analysts remain split on Precigen, with a simple average rating of 4.50 and a performance-weighted rating of 3.24. Two recent ratings have been issued: one “Strong Buy” and one “Buy,” indicating a generally positive outlook, albeit with notable dispersion.

These ratings align with the current price trend, which has seen the stock rise 18.35% recently. However, the low historical performance of one of the participating firms (Citizens, with a 0% win rate) introduces some uncertainty.

Fundamentals

Precigen’s fundamentals show a mixed picture: